Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.

Abstract

BACKGROUND Azathioprine and mercaptopurine (MP) are effective in treating patients with inflammatory bowel disease (IBD). Immunosuppressive effects of thiopurines involve T-cell apoptosis after inhibition of GTPase Ras-related C3 botulinum toxin substrate 1 (Rac1). This study aimed to assess whether expression and activity of Rac1 or phosphorylated ezrin… (More)
DOI: 10.1097/FTD.0000000000000326

Topics

Cite this paper

@article{Seinen2016Rac1AA, title={Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.}, author={Margien L. Seinen and Geerten P. van Nieuw Amerongen and Nanne Klaas de Boer and Chris J. J. Mulder and Jan S M van Bezu and Adriaan Anthonie van Bodegraven}, journal={Therapeutic drug monitoring}, year={2016}, volume={38 5}, pages={621-7} }